Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825229 | Clinical Therapeutics | 2014 | 10 Pages |
Abstract
Pharmacokinetic data suggest that no dose adjustment of empagliflozin is necessary in Japanese patients with T2DM and renal impairment because increases in exposure were <2-fold. Urinary glucose excretion decreased with increasing renal impairment. ClinicalTrials.gov identifier: NCT01581658.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Akiko Sarashina, Kohjiro Ueki, Tomohiro Sasaki, Yuko Tanaka, Kazuki Koiwai, Wataru Sakamoto, Hans J. Woerle, Afshin Salsali, Uli C. Broedl, Sreeraj Macha,